Hormone Replacement Therapy, Breast Cancer Risk, and Menopause
Menopause is a natural transition in a woman’s life, but for many, it comes with symptoms and long-term health considerations that can significantly affect quality of life. Hot flashes, night sweats, vaginal dryness, sleep disruption, mood changes, and accelerated bone loss are just some of the challenges women may face as estrogen levels decline. For decades, hormone replacement therapy (HRT) has been one of the most effective treatments for menopausal symptoms, yet concerns—particularly surrounding breast cancer risk—have led to confusion and hesitation.
Dr. Steven R. Goldstein MD, is a Menopause Specialist NYC and one of the nation’s most respected voices in this field. A highly regarded expert in female hormone replacement therapy and co-author of The Estrogen Alternative, Dr. Goldstein is a Certified Menopause Practitioner of The Menopause Society (formerly the North American Menopause Society) and a Past President of that organization as well as a past President of the International Menopause Society. With more than 25 years in private practice and thousands of women treated, he has devoted his career to helping women better understand their bodies as they approach menopause and make informed decisions about hormone therapy, bone health, and overall well-being. Understanding the Breast Cancer and HRT Conversation Few topics in women’s health have been as widely debated—or misunderstood—as the relationship between hormone replacement therapy and breast cancer. Much of the public discussion stems from earlier studies that grouped different hormones together, despite important biological differences among them. Dr. Goldstein emphasizes that not all estrogens behave the same way in the body, and the type of hormone therapy used matters greatly. One key concept in understanding breast cancer risk and hormone therapy involves SERMs, or Selective Estrogen Receptor Modulators. What Are SERMs and Why Do They Matter? SERMs, such as tamoxifen or Evista (raloxifene), are compounds that act differently depending on the tissue involved. As Dr. Goldstein explains, SERMs are anti-estrogenic in breast tissue while being estrogenic in bone. This dual action is critical. Because SERMs block estrogen activity in the breast, they have been shown to reduce breast cancer risk. At the same time, their estrogen-like activity in bone helps protect against osteoporosis, a major concern for postmenopausal women.
This mechanism helps explain an important and often overlooked finding: women who took Premarin (conjugated equine estrogen) alone in large studies experienced a reduction in breast cancer risk. By contrast, estradiol, the natural estrogen produced by the ovaries, has not demonstrated the same breast cancer–reducing effect in clinical studies. A Breakthrough Approach: Estrogen Plus a SERM One of the historical challenges of estrogen therapy is protecting the uterine lining (endometrium). In women with a uterus, estrogen alone can increase the risk of endometrial cancer, which is why progesterone has traditionally been added to estrogen therapy. However, Pfizer developed an alternative approach by pairing conjugated equine estrogen with a specific SERM called bazedoxifene. This innovative combination resulted in a medication known by the brand name DUAVEE. Dr. Goldstein explains that this combination is particularly compelling from a scientific perspective. Both components—conjugated equine estrogen and bazedoxifene—are anti-estrogenic in breast tissue. For this reason, Dr. Goldstein tells his patients that DUAVEE would not merely avoid increasing breast cancer risk, but would actually reduce it. The Science Behind DUAVEE All SERMs share one important property: they are anti-estrogen in breast tissue. From a mechanistic and scientific standpoint, combining Premarin with a SERM should logically lead to a reduction in breast cancer risk. According to Dr. Goldstein, the biology behind this conclusion is sound and supported by existing evidence. That said, the exact magnitude of breast cancer risk reduction has not been—and likely never will be—quantified in a massive, long-term clinical trial. Such a study would be extraordinarily expensive, and pharmaceutical companies, including Pfizer, have determined that the potential return on investment does not justify the cost. Even without that definitive trial, Dr. Goldstein, a Perimenopause Specialist NYC, notes that the available science strongly supports the concept that
this combination therapy is not harmful to the breast and is likely protective. Benefits Beyond Breast Cancer Risk DUAVEE is FDA-approved for two primary indications: 1. Treatment of moderate to severe menopausal symptoms, such as hot flashes and night sweats 2. Prevention of bone loss associated with menopause However, Dr. Goldstein emphasizes that its benefits do not stop there. Like estrogen, this therapy also provides meaningful support for vaginal health, helping reduce dryness, discomfort, and other genitourinary symptoms that commonly affect postmenopausal women. For many women, this multifaceted benefit profile makes DUAVEE a particularly attractive option—especially for those who are concerned about breast cancer risk but still want effective relief from menopausal symptoms and protection against osteoporosis. Individualized Care Is Essential Despite advances in hormone therapy, Dr. Goldstein stresses that there is no one-size-fits-all solution. Every woman’s medical history, risk factors, symptoms, and personal concerns must be carefully evaluated before choosing a treatment plan. As a clinician who has worked with thousands of women, Dr. Goldstein believes strongly in education and individualized decision-making. His role, as he sees it, is not only to prescribe therapy but to help women understand the science behind their options so they can feel confident and empowered in their choices. Taking the Next Step Menopause is not an illness—it is a life stage. Yet for many women, the symptoms and long-term health risks associated with estrogen loss are very real. Modern hormone therapy, when thoughtfully selected and appropriately prescribed, can offer substantial benefits while addressing
long-standing concerns about safety. If you are approaching menopause or already postmenopausal and experiencing symptoms such as hot flashes, night sweats, vaginal discomfort, or concerns about bone loss, a consultation can make a meaningful difference. Scheduling a visit with Dr. Steven R. Goldstein, MD a top Menopause Specialist NYC provides an opportunity to discuss female hormone replacement therapy in depth, explore the latest scientific evidence, and determine which options best align with your health goals. With decades of experience, leadership in menopause medicine, and a commitment to evidence-based, individualized care, Dr. Goldstein helps women navigate menopause with clarity, confidence, and compassion.